1492 Capital Management LLC 89bio, Inc. Transaction History

1492 Capital Management LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	SELL	$8.13 - $13.77 $406 - $688	-50 Reduced 0.06%	79,168 $921,000
Q4 2023 Feb 12, 2024	BUY	$6.66 - $16.03 $5,421 - $13,048	814 Added 1.04%	79,218 $884,000
Q2 2023 Aug 11, 2023	SELL	$14.15 - $22.03 $509 - $793	-36 Reduced 0.05%	78,404 $1.49 Million
Q1 2023 May 12, 2023	SELL	$10.48 - $16.94 $262 - $423	-25 Reduced 0.03%	78,440 $1.19 Million
Q4 2022 Feb 13, 2023	BUY	$5.52 - $12.73 $433,126 - $998,859	78,465 New	78,465 $998,000

163

108M

73.6K

1.19M

Ticker ETNB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,484,500
Market Cap $417M
Description
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...

Get notified when there are updates to the investment portfolio of 1492 Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on 1492 Capital Management LLC with notifications on news.